• intloko_ibhena_01

I-Oral Semaglutide: I-Needle-Free Breakthrough kwi-Diabetes kunye noLawulo lobunzima

Kwixesha elidlulileyo, i-semaglutide yayifumaneka ngokuyinhloko kwifom ye-injection, eyayinqanda ezinye izigulane ezithintekayo kwiinaliti okanye ukwesaba intlungu. Ngoku, ukuqaliswa kweepilisi zomlomo kuye kwatshintsha umdlalo, okwenza amayeza alungele ngakumbi. Ezi pilisi zomlomo ze-semaglutide zisebenzisa ukuqulunqwa okukhethekileyo okuqinisekisa ukuba iyeza lihlala lizinzile kwindawo ene-acidic yesisu kwaye ikhutshwe ngokufanelekileyo emathunjini, igcina ukusebenza kwayo kwangaphambili ngelixa iphucula ukuthotyelwa kwesigulane.

Ngokumalunga nokusebenza, ithebhulethi yomlomo yenza ngokuhambelana nenaliti. Isenokulawula ngokufanelekileyo iswekile yegazi, iphucule ubuntununtunu be-insulin, kunye nokunceda ekulawuleni ubunzima. Kwizigulane ezinesifo sikashukela sohlobo lwe-2, oku kuthetha ukuba banokufikelela kwiziphumo ezifanayo ekulawuleni iswekile yegazi kunye nokulahlekelwa kwesisindo-ngaphandle kwesidingo se-injection. Kubantu abafuna ngokuyintloko ulawulo lobunzima, ukuqulunqwa komlomo kunika inketho esebenzisekayo ngakumbi, okwenza unyango lwexesha elide lube lula ukunamathela.

Nangona kunjalo, kukho imida ethile yokusebenzisa i-semaglutide yomlomo, njengesidingo sokuyithatha kwisisu esingenalutho kwaye ugweme ukuyithatha ngokutya okuthile. Ke ngoko, abaguli kufuneka badibane nogqirha wabo ngononophelo ngaphambi kokuba basebenzise iyeza ukuqinisekisa ukusetyenziswa okuchanekileyo. Ngokubanzi, ukufika kwe-semaglutide yomlomo kuvumela abantu abaninzi ukuba bazuze kwimiphumo yayo yokwelapha ngokulula kwaye ingaba yinto ephambili kwiinkalo zokulawula isifo sikashukela kunye nokulawula ubunzima kwixesha elizayo.


Ixesha lokuposa: Jul-17-2025